DOLCE: Determining the Impact of Optellum's Lung Cancer Prediction Solution

Prior treatment

• Have received a diagnosis for cancer in the last 5 years
• Have thoracic implants that impact the image appearance of the nodule

Other illness

• Have more than five reported pulmonary nodules of any size or type excluding fully calcified nodules (this criterion is used as a proxy due to the risk of being an infection or metastasis)

Other

• Patients will be excluded from the study if any of the following apply:
• Have one or more additional nodules where any of the following applies:
  • Are already undergoing follow-up according to pulmonary nodule management standard care
  • Pure ground glass opacity (GGO) of \>=5mm in maximum axial diameter for the whole lesion measured using manual electronic callipers
  • \>30mm in maximum axial diameter for the whole lesion measured using manual electronic callipers

• Patients are eligible for the study if all of the following apply:
• Are aged 35 years or above
• Have baseline CT study with at least one incidentally detected solid or part-solid (must have a solid component \>=80%) pulmonary nodule that:
  • is not fully calcified
  • Is 5-30mm inclusive in maximum axial diameter for the whole lesion measured using manual electronic callipers
• Have baseline CT study that includes at least one series that meets all of the following (training for this will be provided):
  • Is of a type that meets VNC instructions for use
  • Comprises at least one full-inspiration breath-hold scans without a high degree of contrast media and does not exhibit quality issues (e.g., motion artefacts)